First go here and remind yourself about the stunning results of a small investigator trial and the size of the DN patient population, which may be larger than all 19 existing indications combined: irDOTquestcorDOTcom/releasedetail.cfm?releaseid=532121.
Then go here and notice that preminiary results are expected in June 2014 and trial completion is expected in December 2014: clinicaltrialsDOTgov/ct2/show/results/NCT01601236?term=diabetic+nephropathy+and+ACTH&rank=1.
Similar to sarcoidosis, there are few if any treatments for DN, again meaning Acthar will effectively be a first line therapy.
Finally, note on the QCOR site--still 14 positions advertised for pulmonology sales rep plus a few support positions. My estimate: QCOR is aiming for a field force of 30.